Clinical Trials – A New Ray of Hope for Celiac Disease Patients
Celimmune (AMG 714)
On the other hand, Celimmune stands out as a clinical development-stage immunotherapy firm, which is dedicated to forming transformation therapies. These therapies aim to relieve the symptoms of celiac disease along refractory celiac disease and other autoimmune diseases. The company licensed AMG 715 right from Amgen last 2015. AMG 714 pertains to a monoclonal antibody, which targets the IL-15, a type of cytokine that has been proven to be one of the reasons why there’s a loss of tolerance into food antigens. It has been linked to celiac disease as well as other autoimmune diseases.
